Features - Bayer

Filter

Current filters:

Bayer

Popular Filters

298 to 322 of 343 results

Outlook for VTE treatment and prophylaxis market

14-12-2011

Driven primarily by the launches and strong uptake of oral anticoagulants, the combined markets for drugs…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

News briefs from breast cancer meeting

12-12-2011

In further news from the the San Antonio Breast Cancer Symposium (SABCS) that took place in Texas, USA…

AlgetaAlpharadinBayerGlaxoSmithKlineOncologyPharmaceuticalResearchTykerb

Mixed views on drospirenone OCs

09-12-2011

The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

BayerDrospirenone and EstradiolNorth AmericaPharmaceuticalRegulationReproductiveWomen's HealthYasminYaz

Phase III trial of Regeneron and Bayer’s Eylea initiated in China

29-11-2011

USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) and German partner Bayer (BAY: DE) have initiated…

Asia-PacificBayerEyleaOphthalmicsPharmaceuticalRegeneronResearch

FDA approves Regeneron’s Eylea for wet age-related macular degeneration

21-11-2011

Following unanimous advisory panel support for the drug, the US Food and Drug Administration has approved…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Bayer plans further capital spending of 1.8 billion euros in Asia

16-11-2011

German pharma, crop and material sciences group Bayer (BAY: DE) this morning disclosed plans to further…

Asia-PacificBayerFinancialMarkets & MarketingPharmaceutical

Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif

15-11-2011

US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) says that the Phase…

BayerGenzymeLemtradaNeurologicalPharmaceuticalRebifResearchSanofi

Bayer 3rd-qtr 2011 results show strong Pharma offsetting weakness in MatSci

27-10-2011

German pharma, crop and materials sciences group Bayer AG (BAY: DE) posted a healthy set of third-quarter…

BayerFinancialPharmaceutical

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Bayer signs MoU to establish pharmaceutical production in Russia

11-10-2011

In a move that indicates it is going to join the ranks of other drug giants by making major investments…

BayerEuropeFinancialMarkets & MarketingPharmaceuticalResearch

Bayer celebrates 100 years in Japan, planning continued growth there despite difficult conditions

05-10-2011

Germany’s pharma, and material and crop sciences group Bayer (BAY: DE) says it plans to expand its…

Asia-PacificBayerFinancialPharmaceuticalResearch

US FDA communicates concern about drospirenone-containing birth control pills

27-09-2011

The US Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion,…

BayerDrospirenone and Ethinyl EstradiolNorth AmericaPharmaceuticalRegulationReproductiveYasminYaz

EMA advisory panel backs Bayer’s Xarelto for AF-related stroke prevention and DVT

26-09-2011

There was more good news for Bayer HealthCare, the pharma unit of Germany’s Bayer AG (BAY: DE),…

BayerCardio-vascularEuropePharmaceuticalRegulationXarelto

Positive first Phase III trial of an alpha-pharmaceutical, Bayer’s Alpharadin

26-09-2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very…

AlgetaAlpharadinBayerOncologyPharmaceuticalResearch

US FDA advisory panel backs approval of Bayer/J&J’s Xarelto for stroke prevention

09-09-2011

There must have been a palpable sigh of relief last night across Leverkusen, the headquarters of Germany’s…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Disappointing FDA briefing papers on Bayer/J&J’s Xarelto

07-09-2011

US Food and Drug Administration staffers posted a negative picture for German drug major Bayer (BAY:…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Changing the mood of Brazilian antidepressant market; fake Levitra

24-08-2011

The Vice President of Brazil’s Superior Court of Justice (STJ), Minister Felix Fischer, has restored…

BayerGenericsLevitraLexaproLundbeckNeurologicalPharmaceuticalRegulationReproductiveSouth America

US FDA fast-tracks Bayer and Algeta’s prostate drug Alpharadin

23-08-2011

Germany’s Bayer (BAY: DE) said this morning that its investigational compound Alpharadin (radium-223…

AlgetaAlpharadinBayerNorth AmericaOncologyPharmaceuticalRegulation

Bayer reprimanded for breaches of the ABPI Code by tweeting on Rx drugs

19-08-2011

The UK Prescription Medicines Code of Practice Authority (PMCPA) has reprimanded Bayer Healthcare, a…

BayerEuropeLevitraMarkets & MarketingPharmaceuticalRegulationSativex

US FDA delays decision on Regeneron’s wet AMD drug Eylea

18-08-2011

US biotech firm Regeneron Pharmaceuticals. (Nasdaq: REGN) says that it has received notification from…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsRegeneronRegulation

Bayer makes moxifloxacin available to help WHO TB program in China

15-08-2011

Bayer HealthCare, a unit of Germany’s Bayer AG (BAY: DE), has agreed to support the World Health…

Antibiotics and Infectious diseasesAsia-PacificBayerMarkets & MarketingMoxifloxacinPharmaceutical

298 to 322 of 343 results

Back to top